

Req. — Jan DeLoval

Access DB# 131231

## SEARCH REQUEST FORM

Scientific and Technical Information Center

Applicant's Full Name: Sabiha Qazi Examiner #: 74141 Date: 8/29/01  
Phone: 1616 Phone Number (X) 20622 Serial Number: 10/C 36819  
Lab and Bldg Room Location: 4670 Rm 4A45 Results Format Preferred (circle): PAPER DISK E-MAIL  
Note that once search is submitted, please prioritize searches in order of need.

1. Provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched.  
2. List the related species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or  
3. List the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if  
4. Attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Use of Biologically active Vrt D  
Inventor (please, provide full names): HAYES, COLLEEN E. et al.

Priority Filing Date: HA Continuation of 07/469,985  
12/21/99  
1. Keep only Searches Only\* Please include all pertinent information (patent, child, divisional, or issued patent numbers) along with the  
2. Indicate which was her.

A method of treating inflammatory  
bowel disease by 1- $\alpha$  hydroxyvitamin D<sub>2</sub>  
Inflammatory bowel disease is  
selected from ulcerative colitis &  
Crohn's disease.

Thank you

SEARCH ONLY	Type of Search	Vendors and cost where applicable
<u>Qazi</u>	NA Sequence (#) _____	STN <u>✓</u>
	AA Sequence (#) _____	Dialog _____
	Structure (#) <u>✓</u>	Questel/Orbit _____
	Bibliographic _____	Dr.Link _____
	Litigation _____	Lexis/Nexis _____
	Fulltext _____	Sequence systems _____
	Patent Family _____	WWW/Internet _____
	Other _____	Other (specify) _____

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:56:00 ON 05 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 SEP 2004 HIGHEST RN 739335-06-9

DICTIONARY FILE UPDATES: 3 SEP 2004 HIGHEST RN 739335-06-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide can tot 193

L93 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN

RN 131918-61-1 REGISTRY

CN 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,  
(1 $\alpha$ ,3 $\beta$ ,7E,22E) - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 19-Nor-1,25-dihydroxyvitamin D2

CN Paricalcitol

CN Zemplar

FS STEREOSEARCH

DR 539856-25-2

MF C27 H44 O3

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

DT.CA Caplus document type: Journal; Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); OCCU (Occurrence); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

90 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 90 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:134693

REFERENCE 2: 141:134637

REFERENCE 3: 141:82701

REFERENCE 4: 141:65567

REFERENCE 5: 140:412093

REFERENCE 6: 140:334734

REFERENCE 7: 140:332505

REFERENCE 8: 140:327062

REFERENCE 9: 140:281507

REFERENCE 10: 140:276190

L93 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN

RN 54573-75-0 REGISTRY

CN 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,  
 (1 $\alpha$ ,3 $\beta$ ,5Z,7E,22E) - (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1-Hydroxyergocalciferol

CN 1-Hydroxyvitamin D2

CN 1 $\alpha$ -Hydroxyergocalciferol

CN 1 $\alpha$ -Hydroxyvitamin D2

CN Doxercalciferol

CN Hectorol

CN TSA 840

FS STEREOSEARCH

DR 125285-48-5, 87649-67-0

MF C28 H44 O2

LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PHAR, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL


(\*File contains numerically searchable property data)

DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); FORM (Formation,

nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties);  
 RACT (Reactant or reagent); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological  
 study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent);  
 USES (Uses)

Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

139 REFERENCES IN FILE CA (1907 TO DATE)  
 139 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:167976  
 REFERENCE 2: 141:65567  
 REFERENCE 3: 141:64828  
 REFERENCE 4: 140:406808  
 REFERENCE 5: 140:332505  
 REFERENCE 6: 140:327062  
 REFERENCE 7: 140:281507  
 REFERENCE 8: 140:276190  
 REFERENCE 9: 140:259103  
 REFERENCE 10: 140:259102

=> d his

(FILE 'HOME' ENTERED AT 14:08:35 ON 05 SEP 2004)  
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 14:08:46 ON 05 SEP 2004  
 L1 92 S (1ALPHA OR 1 ALPHA OR 1 A) (HYDROXYVITAMIN OR HYDROXY VITAMI

FILE 'REGISTRY' ENTERED AT 14:09:21 ON 05 SEP 2004  
 L2 1 S 54573-75-0

L3 0 S 54573-75-0/CRN

FILE 'HCAPLUS' ENTERED AT 14:09:44 ON 05 SEP 2004

L4 139 S L2  
L5 9 S (1ALPHA OR 1 ALPHA OR 1 A) () (HYDROXYERGOCALCIFEROL OR HYDROXY  
L6 26 S DOXERCALCIFEROL OR DOXER CALCIFEROL OR HECTOROL OR TSA840 OR  
L7 0 S 9 10 SECOERGOSTA 5 7 10 19 22 TETRAENE 1 3 DIOL  
L8 159 S L1,L4,L5,L6  
E CROHN/CT  
L9 0 S L8 AND CROHN?  
E E6+ALL  
E ULCERATIVE COLITIS/CT  
E E3+ALL  
L10 0 S L8 AND E2  
L11 1 S L8 AND ?ULCER?  
L12 0 S L8 AND ?COLIT?  
L13 1 S L8 AND ?COLIC?  
L14 32 S L8 AND ?INTESTIN?  
L15 1 S L14 AND L11,L13  
L16 8 S L8 AND ?COLON? AND L14  
L17 0 S L8 AND IBD  
L18 0 S L8 AND ?INFLAM? (L) BOWEL?  
E INFLAMMATORY BOWEL/CT  
E E4+ALL  
L19 0 S L8 AND E2  
L20 2 S (US20020128241 OR US63548939)/PN OR WO2000-US34913/AP,PRN  
E HAYES C/AU  
L21 85 S E3,E77-E79  
E NASHOLD F/AU  
L22 17 S E3-E6  
L23 0 S L20 AND L8  
L24 1 S L21,L22 AND L8  
SEL RN L20

FILE 'REGISTRY' ENTERED AT 14:17:34 ON 05 SEP 2004

L25 22 S E1-E22  
L26 1 S L25 AND C28H44O3  
E C28H44O2/MF  
L27 41 S E3 AND C6/ES AND C5-C6/ES AND 3/NR  
L28 12 S L27 AND 5 7 10 19 22 TETRAENE AND 1 3 DIOL  
L29 8 S L28 NOT D/ELS  
L30 7 S L29 NOT L2  
L31 6 S L30 NOT T/ELS  
SEL RN  
L32 0 S E1-E6/CRN

FILE 'HCAPLUS' ENTERED AT 14:20:59 ON 05 SEP 2004

L33 24 S L31  
L34 0 S L33 AND (IBD OR ?INFLAM? (L) BOWEL? OR ?CROHN? OR ?ULCER? (L) (CO  
L35 167 S L8,L33  
E INTESTINE, DISEASE/CT  
L36 6 S E2-E54 AND L35  
E E3+ALL  
L37 7 S L35 AND E11,E12,E10+NT  
E E84+ALL  
L38 17 S L35 AND E5,E6,E4+NT  
L39 17 S L35 AND (E12+OLD,NT,PFT,RT OR E13+OLD,NT,PFT,RT OR E14+OLD,NT  
E E3+ALL  
L40 29 S L35 AND (E3+OLD,NT,PFT,RT OR E86+OLD,NT,PFT,RT OR E87+OLD,NT,  
L41 29 S L36-L40  
L42 18 S L41 AND (PY<=1999 OR PRY<=1999 OR AY<=1999)  
L43 12 S L42 NOT ?NEOPLAS?  
L44 6 S L43 NOT (HEPATOMA/TI OR OSTEOPOROSIS/CW OR RICKETS/CW)

L45 4 S L44 NOT (LIGAND OR SUPPLEMENT)/TI  
L46 6 S L42 NOT L43  
L47 5 S L46 AND COLON NOT 3/SC  
L48 10 S L24,L45,L47

FILE 'MEDLINE' ENTERED AT 14:30:25 ON 05 SEP 2004

L49 62 S L8 OR L31  
E CROHN/CT  
E E5+ALL  
L50 0 S L49 AND E9+NT  
E E9+ALL  
L51 0 S L49 AND (IBD OR ?INFLAM?(L)BOWEL? OR ?CROHN? OR ?ULCER?(L)COL

FILE 'EMBASE' ENTERED AT 14:31:26 ON 05 SEP 2004

L52 151 S L8 OR L31  
E ERGOCALCIFEROL/CT  
E E3+ALL  
L53 5089 S E1  
L54 5301 S E1/BI  
E ERGOCALCIFEROL/CT  
E E10+ALL  
L55 115 S E9  
L56 5432 S L52-L55  
L57 16 S L56 AND ?CROHN?  
L58 12 S L56 AND (IBD OR ?INFLAM?(L)BOWEL? OR ?ULCER?(L)COLIT?)  
E CROHN/CT  
E E5+ALL  
L59 14 S L56 AND E1+NT  
E IBD/CT  
E INFLAMMATORY BOWEL/CT  
E E4+ALL  
L60 24 S L56 AND E2+NT  
E ULCERATIVE COLITIS/CT  
E E3+ALL  
L61 6 S L56 AND E1+NT  
L62 27 S L57-L61  
L63 23 S L62 AND PY<=1999

FILE 'REGISTRY' ENTERED AT 14:38:36 ON 05 SEP 2004

L64 3 S 50-14-6 OR 50809-47-7 OR 8042-78-2

FILE 'EMBASE' ENTERED AT 14:39:14 ON 05 SEP 2004

L65 0 S L52 AND L62

FILE 'MEDLINE' ENTERED AT 14:39:21 ON 05 SEP 2004

FILE 'WPIX' ENTERED AT 14:39:42 ON 05 SEP 2004

L66 45 S L1/BIX OR L5/BIX OR L6/BIX  
L67 5 S (19 NOR 1 25 ()) (DIHYDROXYVITAMIN OR DIHYDROXY VITAMIN OR DI H  
E 19 NOR 1 25 DIHYDROXYVITAMIN D2/CN  
E 19-NOR-1,25-DIHYDROXYVITAMIN D2/CN  
L68 1 S E3  
E RA3C75/DCN  
L69 4 S E3-E7  
E DOXERCALCIFEROL/CN  
L70 1 S E3  
E RA7AA1/DCN  
L71 7 S E3-E8  
L72 53 S L66,L67,L69,L71  
L73 0 S L72 AND ?CROHN?/BIX  
L74 0 S L72 AND (IBD OR ?INFLAM?(L)BOWEL? OR ?ULCER?(L) (COLON OR COLI  
L75 7 S L72 AND ?INTESTIN?/BIX  
L76 1 S L72 AND (B14-E10C OR C14-E10C)/MC

L77 1 S L72 AND (B14-E10? OR C14-E10?)/MC  
L78 0 S L71 AND A61P001/IPC  
L79 1 S L71 AND P73?/M0,M1,M2,M3,M4,M5,M6  
L80 1 S L72 AND (B12-J01 OR C12-J01)/MC  
L81 8 S L75-L80

FILE 'BIOSIS' ENTERED AT 14:52:19 ON 05 SEP 2004

L82 56 S L8 OR L31

FILE 'HCAPLUS' ENTERED AT 14:52:54 ON 05 SEP 2004

L83 13 S 19 NOR 1 25 () (DIHYDROXYVITAMIN OR DIHYDROXY VITAMIN OR DI HY

FILE 'REGISTRY' ENTERED AT 14:53:32 ON 05 SEP 2004

L84 1 S 131918-61-1

L85 0 S 131918-61-1/CRN

FILE 'HCAPLUS' ENTERED AT 14:53:53 ON 05 SEP 2004

L86 90 S L84

L87 62 S PARICALCITOL OR ZEMPLAR

L88 98 S L83,L86,L87

L89 2 S L88 AND ?CROHN?

L90 2 S L88 AND (IBD OR ?INFLAM?(L)BOWEL? OR ?ULCER?(L)COLIT?)

L91 2 S L89,L90

L92 2 S L91 AND L4-L24,L33-L48,L64,L83,L86-L91

FILE 'REGISTRY' ENTERED AT 14:55:50 ON 05 SEP 2004

L93 2 S L84 OR L2

FILE 'REGISTRY' ENTERED AT 14:56:00 ON 05 SEP 2004

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:56:14 ON 05 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Sep 2004 VOL 141 ISS 11

FILE LAST UPDATED: 3 Sep 2004 (20040903/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 192 all hitstr tot

L92 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:455025 HCAPLUS

DN 139:30856

ED Entered STN: .13 Jun 2003

TI Treating vitamin D responsive diseases

IN Hayes, Colleen E.; Nashold, Faye E.

PA Northern Lights Pharmaceuticals, LLC, USA

SO U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 469,985.  
CODEN: USXXCO

DT Patent

LA English

IC ICM A61K038-20

ICS A61K031-59

NCL 514167000; 424085200

CC 1-12 (Pharmacology)

Section cross-reference(s): 2, 15, 18, 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003109506	A1	20030612	US 2002-170746	20020613 <--
	US 6358939	B1	20020319	US 1999-469985	19991221
	WO 2001046132	A1	20010628	WO 2000-US34913	20001221 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	WO 2003106629	A2	20031224	WO 2003-US18558	20030611
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-469985	A2	19991221		
	WO 2000-US34913	A	20001221	<--	
	US 2002-170746	A	20020613		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	US 2003109506	ICM	A61K038-20
		ICS	A61K031-59
		NCL	514167000; 424085200
	US 2003109506	ECLA	A61K031/59; A61K031/59P <--
AB	The invention relates to therapeutics for the prevention and treatment of vitamin D responsive diseases in humans, as well as other animals, through the use of biol. active vitamin D compds. in combination with at least one other immunomodulatory compound such as interleukin-10, interleukin-4, or a TNF- $\alpha$ inhibitor.		
ST	vitamin D IL10 immunomodulator <b>antiinflammatory</b> human <b>inflammatory bowel</b> disease; calcitriol cytokine hypercalcemic osteoporosis renal osteodystrophy psoriasis IBD immunomodulator; transdermal patch calcitriol drug screening multiple sclerosis arthritis human; TNFa inhibitor <b>antiinflammatory</b> calcitriol interleukin human <b>inflammatory bowel</b> disease		
IT	Intestine, disease ( <b>Crohn's</b> ; treating vitamin D responsive diseases)		
IT	Intestine, disease (inflammatory; treating vitamin D responsive diseases)		
IT	Bone, disease		



(renal osteodystrophy; treating vitamin D responsive diseases)

IT Drug delivery systems  
(transdermal, controlled-release; treating vitamin D responsive diseases)

IT Anti-inflammatory agents  
Arthritis  
Blood serum  
Disease, animal  
Drug interactions  
Drug screening  
Feces  
Human  
Immunomodulators  
Multiple sclerosis  
Osteoporosis  
Psoriasis  
(treating vitamin D responsive diseases)

IT Hemoglobins  
Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(treating vitamin D responsive diseases)

IT Cytokines  
Interleukin 10  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(treating vitamin D responsive diseases)

IT Interleukin 4  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(treating vitamin D responsive diseases)

IT Intestine, disease  
(**ulcerative colitis**; treating vitamin D responsive diseases)

IT 7440-70-2, Calcium, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hypercalcemia; treating vitamin D responsive diseases)

IT 50-24-8, Prednisolone 1406-16-2, Vitamin D 32222-06-3, 1,25-Dihydroxyvitamin D3 41294-56-8, 1 $\alpha$ -Hydroxyvitamin D3  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(treating vitamin D responsive diseases)

IT 103656-37-7 131875-08-6, KH1060 **131918-61-1** 195051-26-4  
215714-87-7 233268-76-3, LG 190090 233268-77-4, LG190119  
233268-78-5, LG190155 233268-79-6, LG 190176 233268-81-0, LG 190178  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(treating vitamin D responsive diseases)


IT **131918-61-1**  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(treating vitamin D responsive diseases)

RN 131918-61-1 HCAPLUS

CN 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,  
(1 $\alpha$ ,3 $\beta$ ,7E,22E) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L92 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:435039 HCAPLUS  
 DN 135:41381  
 ED Entered STN: 15 Jun 2001  
 TI Treatment of **inflammatory bowel** disease with vitamin D compounds  
 IN Cantorna, Margherita T.  
 PA The Penn State Research Foundation, USA  
 SO PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C07C401-00  
 CC 2-10 (Mammalian Hormones)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042205	A2	20010614	WO 2000-US42393	20001130
	WO 2001042205	A3	20020321		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1233942	A2	20020828	EP 2000-992552	20001130
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003516386	T2	20030513	JP 2001-543506	20001130
PRAI	US 1999-168501P	P	19991202		
	US 2000-197827P	P	20000414		
	US 2000-208632P	P	20000601		
	US 2000-231906P	P	20000911		
	WO 2000-US42393	W	20001130		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001042205	ICM	C07C401-00

OS MARPAT 135:41381

AB A method of treating **inflammatory bowel** disease, particularly **ulcerative colitis** and **Crohn's** disease, is disclosed. The method involves administering a vitamin D compound in an amount effective to treat the disease. The administration of a vitamin D compound also prevents the development of or delays the onset of **inflammatory bowel** disease in susceptible individuals.

ST **inflammatory bowel** disease **ulcerative**

- colitis Crohns** vitamin D treatment
- IT Intestine, disease  
(**Crohn's**; treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT Intestine, disease  
(**inflammatory**; treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT Diet  
(low calcium; treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT Intestine, disease  
(**ulcerative colitis**; treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT 1406-16-2, vitamin D  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(deficiency; treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT 32222-06-3D, analogs 41294-56-8, 1 $\alpha$ -Hydroxyvitamin D3  
60133-18-8, 1,25-Dihydroxyvitamin D2 75363-22-3 108646-38-4,  
1 $\alpha$ ,25-Dihydroxyvitamin D3 triacetate **131918-61-1**  
133876-00-3, 1 $\alpha$ -Hydroxyvitamin D 156196-99-5 195051-26-4  
217093-03-3  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT 7440-70-2, Calcium, biological studies  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(treatment of **inflammatory bowel** disease with vitamin D compds.)
- IT **131918-61-1**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(treatment of **inflammatory bowel** disease with vitamin D compds.)
- RN 131918-61-1 HCAPLUS
- CN 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,  
(1 $\alpha$ ,3 $\beta$ ,7E,22E) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

